Alpha 2.0
Login Register
» Authors » Umut Demirci

Umut Demirci

Explore the profile of Umut Demirci including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 105
Citations 557
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Suleyman Buyukberber
Mustafa Benekli
Ugur Coskun
Berna Oksuzoglu
Meltem Baykara
Nuri Karadurmus
Mahmut Gumus
Ahmet Bilici
Olcun Umit Unal
Saadettin Kilickap
Published In
Asian Pac J Cancer Prev
J BUON
Med Oncol
J Cancer Res Clin Oncol
J Oncol Pharm Pract
Affiliations
Soon will be listed here.
Recent Articles
1.
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Kalinsky K, Bianchini G, Hamilton E, Graff S, Park K, Jeselsohn R, et al.
J Clin Oncol . 2024 Dec; 43(9):1101-1112. PMID: 39693591
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer...
2.
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
Karci E, Bilici A, Bayram B, Celayir M, Ozyurt N, Uluc B, et al.
Cancers (Basel) . 2024 Oct; 16(19). PMID: 39410009
Following the results of the phase 3 KEYNOTE-522 trial, the U.S. Food and Drug Administration approved pembrolizumab, a humanized IgG4 kappa monoclonal antibody, in combination with neoadjuvant chemotherapy as a...
3.
Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study
Esin E, Yildirim H, Oksuzoglu B, Markoc F, Guntekin S, Bilgetekin I, et al.
J Clin Med . 2024 Sep; 13(17). PMID: 39274541
Therapeutic decisions in early breast cancer are based on clinico-pathological features which are subject to intra- and inter-observer variability. This single-center decision impact study aimed to evaluate the effects of...
4.
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study
Karadurmus N, Kaplan M, Sendur M, Urun Y, Demirci U, Karaca S, et al.
Curr Med Res Opin . 2024 May; 40(7):1171-1178. PMID: 38809230
Objective: To evaluate the efficacy and safety of nivolumab in the second-line (2L) or later-line (LL) treatment of patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) in real-life setting...
5.
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
Kilickap S, Ozturk A, Karadurmus N, Korkmaz T, Yumuk P, Cicin I, et al.
Medicine (Baltimore) . 2024 May; 103(21):e37972. PMID: 38787994
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study...
6.
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Guven D, Aykan M, Muglu H, Bayram E, Helvaci K, Dursun B, et al.
Cancer Med . 2023 Dec; 13(1):e6869. PMID: 38140782
Introduction: The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and the combination of...
7.
Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye
Cicin I, Karadurmus N, Bilici A, Bahsi T, Sendur M, Demirci U, et al.
Future Oncol . 2023 Nov; 20(15):1031-1045. PMID: 38014519
According to current evidence, testing for germline pathogenic variants in newly diagnosed breast cancer (BC) patients has the potential to reduce the burden of the disease through targeted therapies and...
8.
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
Akyildiz A, Guven D, Ozluk A, Ismayilov R, Mutlu E, Umit Unal O, et al.
Medicine (Baltimore) . 2023 Nov; 102(45):e35950. PMID: 37960746
The aim of the study was to evaluate the real-world clinical outcomes of atezolizumab and bevacizumab (Atez/Bev) as the initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65...
9.
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
Guner G, Aktas B, Bugdayci Basal F, Demirkazik A, Gursoy P, Demirci U, et al.
J Cancer Res Clin Oncol . 2023 Jul; 149(14):13271-13277. PMID: 37480524
Purpose: Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3-5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The...
10.
Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling
Ozdemir Z, Cevik E, Cakmak Oksuzoglu O, Dogan M, Ates O, Esin E, et al.
Mutat Res . 2023 Jul; 827:111831. PMID: 37453313
Objective: Hereditary cancer syndromes constitute 5-10% of all cancers. The development of next-generation sequencing technologies has made it possible to examine many hereditary cancer syndrome-causing genes in a single panel....